SCHEMBL26089705

SCHEMBL26089705

CCN(CC)c1ccc(/C=C/c2cc[n+](CCCCCCCCCCCC[n+]3ccc(/C=C/c4ccc(N(CC)CC)cc4)c(C)c3)cc2C)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM2 P08172 2/20 0.55
▸ CHRM4 P08173 2/20 0.55
▸ CHRM5 P08912 2/20 0.55
▸ CHRM1 P11229 2/20 0.55
▸ CHRM3 P20309 2/20 0.55
▸ KDM4A O75164 4/20 0.51
▸ KDM2A Q9Y2K7 4/20 0.51
▸ INSR P06213 2/20 0.45
▸ CHAT P28329 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ ALDH3A1 P30838 1/20 0.40
▸ ALDH1A3 P47895 1/20 0.40
▸ MAPT P10636 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ BCHE P06276 2/20 0.38
▸ ACHE P22303 2/20 0.38
▸ APP P05067 1/20 0.38
▸ HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26093619 1.00 CHRM2 (0.55) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL26092007 1.00 CHRM2 (0.55) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL26091229 1.00 CHRM2 (0.55) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL26093245 1.00 CHRM2 (0.55) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL26092898 1.00 CHRM2 (0.55) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL26093456 1.00 CHRM2 (0.55) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL12533267 1.00 CHRM2 (0.55) CHRM2CHRM4CHRM5CHRM1CHRM3
Bromide SCHEMBL30379194 0.99 CHRM2 (0.57) CHRM2CHRM4CHRM5CHRM1CHRM3
Bromide SCHEMBL30379542 0.99 CHRM2 (0.57) CHRM2CHRM4CHRM5CHRM1CHRM3
Bromide SCHEMBL30379376 0.99 CHRM2 (0.57) CHRM2CHRM4CHRM5CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023067170-A1 COMPOUNDS FOR THE TREATMENT OF MALARIA FUNDACIÓ INSTITUT DE BIOENGINYERIA DE CATALUNYA (ES) 2023-04-27 — — WO claimed
US-20240415825-A1 COMPOUNDS FOR THE TREATMENT OF MALARIA Fundación Privada Instituto De Salud Global Barcelona (ES) 2024-12-19 — — US disclosed
WO-2023067170-A1 COMPOUNDS FOR THE TREATMENT OF MALARIA FUNDACIÓ INSTITUT DE BIOENGINYERIA DE CATALUNYA (ES) 2023-04-27 — — WO disclosed
WO-2023067170-A1 COMPOUNDS FOR THE TREATMENT OF MALARIA FUNDACIÓ INSTITUT DE BIOENGINYERIA DE CATALUNYA (ES) 2023-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240415825-A1 COMPOUNDS FOR THE TREATMENT OF MALARIA ABAT, GLS2, CPS1 CHRM2 2286/4885CHRM4 3290/4885CHRM5 2321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback